Physician profile
Phillip Gray
NPI 1093786386
$3,668.28
in general payments reported to CMS, 2019-2025
35 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $339 · 2021: $207 · 2022: $566 · 2023: $540 · 2024: $436 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.96 | 2021-2025 | |
| Pfizer INC. | $484.29 | 2019-2025 | |
| Novo Nordisk INC | $473.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $447.24 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.47 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $138.03 | 2019-2021 | |
| Lilly USA, LLC | $123.80 | 2019 | |
| Glaxosmithkline, LLC. | $121.12 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $115.41 | 2019-2021 | |
| Dexcom, INC. | $102.05 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $90.05 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $82.66 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $72.93 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $68.00 | 2022 | |
| Allergan, INC. | $55.71 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54.11 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.32 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $34.61 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $30.79 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $30.49 | 2022-2024 | |
| Amarin Pharma, INC. | $26.79 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.38 | 2024 | Voquezna |
| Astellas Pharma US INC | $22.36 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $20.01 | 2023 | Rexulti |
| Cranial Technologies, INC | $18.24 | 2022 | |
| Daiichi Sankyo INC. | $17.90 | 2022 | |
| Shire North American Group INC | $17.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.52 | 2021 | |
| Shield Therapeutics INC | $15.93 | 2025 | |
| Esperion Therapeutics, INC. | $15.79 | 2020 | |
| Mylan Specialty L.P. | $14.94 | 2022 | |
| Almatica Pharma LLC | $12.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.